Clinical Significance of <i>TNFRSF1A</i>36T/C Polymorphism in Cachectic Patients with Chronic Heart Failure

• Main Authors: Grzegorz Sobieszek, Tomasz Powrózek, Aneta Skwarek-Dziekanowska, Teresa Małecka-Massalska
• Format: Article
• Language: English
• Published: MDPI AG 2021-03-01
• Series: Journal of Clinical Medicine
• Subjects: chronic heart failure; cachexia; TNFRSF1A; cardiac cachexia
• Online Access: https://www.mdpi.com/2077-0383/10/5/1095

We enrolled 142 CHF individuals who underwent cardiac and nutritional screening in order to assess cardiac performance and nutritional status. The relationship between <i>TNFRSF1A</i> rs767455 genotypes and patients’ features was investigated. <b>Results: </b>A greater distribution of the TT genotype among cachectic patients in contrast to non-cachectic individuals was found (TT frequencies of 62.9% and 37.1%, respectively; <i>p </i>= 0.013). We noted a significantly lower albumin concentration (<i>p </i>= 0.039) and higher C-reactive protein (CRP) levels (<i>p </i>= 0.019) in patients with the TT genotype. Regarding cardiac parameters, CHF individuals bearing the TT genotype demonstrated a significant reduction in ejection fraction (EF) (<i>p </i>= 0.033) in contrast to other genotype carriers; moreover, they had a significantly higher concentration of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in the blood (<i>p </i>= 0.018). We also noted a lower frequency of TT genotype carriers among individuals qualified as grades I or II of the New York Heart Association (NYHA) (<i>p </i>= 0.006). The multivariable analysis selected the TT genotype as an unfavorable factor related to a higher chance of cachexia in CHF patients (Odds ratio (OR) = 2.56; <i>p </i>= 0.036). <b>Conclusions: </b>The rs767455TT genotype of <i>TNFRSF1A </i>can be considered as an unfavorable factor related to a higher risk of cachexia in CHF patients.